Cellromax Science KRX:471820KOSDAQ
셀로맥스사이언스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, Cellromax Science reported revenue of ₩5.1bn, down 21.2% year on year, and operating profit of ₩981m. Cellromax Science (셀로맥스사이언스) appeared in 0 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 23 with 1 article.
Cellromax Science quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩5.1bn | -21.2% | ₩981m margin 19.3% | – |
| Q1 2026 | ₩4.7bn | -20.4% | ₩348m margin 7.4% | – |
| Q4 2025 derived | ₩4.5bn | -18.5% | ₩86m margin 1.9% | – |
| Q3 2025 | ₩5.3bn | -2.5% | ₩737m margin 13.8% | ₩757m |
| Q2 2025 | ₩6.5bn | +18.0% | ₩1.2bn margin 17.9% | ₩1.2bn |
| Q1 2025 | ₩5.9bn | +14.0% | ₩853m margin 14.4% | ₩739m |
| Q4 2024 derived | ₩5.5bn | – | ₩1.0bn margin 18.9% | – |
| Q3 2024 | ₩5.5bn | – | ₩1.2bn margin 22.2% | ₩1.3bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Cellromax Science top stories 2 weeks, by number of outlets
- 1